Enlaza Therapeutics gains $100M for covalent biologic cancer drugs

The latest stories trending on MedCity News.

Editor's Pick

Top Story J.P. Morgan Leads $100M Financing for Startup's R&D of Covalent Biologic Drugs for Cancer Enlaza Therapeutics' drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. Protecting Healthcare from Cyber Attacks: A Crucial Discussion at INVEST 2024 The recent cybersecurity incident at Change Healthcare has highlighted the urgent need for stronger defenses against cyber threats in the healthcare industry. Don't miss this discussion at INVEST 2024.   Join Nitin Natarajan, Deputy Director of the Cybersecurity and Infrastructure Security Agency (CISA), and Arundhati Parmar, Editor-in-Chief MedCity News, in a fireside chat to address the pressing questions: What can be done to prevent cyber attacks? Do policies need to change? How much investment is required to secure data?   Don't Miss Out - Get Your Tickets Now

Featured News

Shifting the Payer Landscape with Health Tech A new eBook from HLTH and MedCity News captures how health insurers and their partners are using health tech to improve the patient experience, hea Healthcare Moves: A Monthly Summary of Hires and Layoffs Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry. MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Adaeze Enekwechi, CEO of Cayaba Care In this month's episode, Senior Reporter Katie Adams explored some executive hires and exits that recently occurred in the healthcare world, as well as layoffs affecting the industry. She also interviewed Adaeze Enekwechi, who became CEO of Cayaba Care this month.

Resources

MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates? In this episode, we're joined by John Auerbach, senior vice president of federal health at consulting firm ICF. He discusses rising preeclampsia rates and how stakeholders need to act. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe